Two Phase III Trials Show Increase In PFS In Two Distinct Patient Populations
Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%
Two Conflicting Studies Presented at ASCO 2013, FDA Called Upon To Sort Through The Data
Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events
Votrient Trial Meets PFS Endpoint In Epithelial Ovarian Cancer
Afinitor Extends PFS In Women With EGFR-2 Positive Disease
Analysis Reveals CAIX Subgroup Responsive to Rencarex Therapy
Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III
CTEP-Approved Trials For the Month of June
FDA Approves Two Oral Drugs For Metastatic Melanoma
Trending Stories
- A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- George Sigounas named the first-ever chief science advisor at NCI
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Makary: Level of evidence is an artificial and dogmatic construct
- Reimagining cancer care for a new generation of patients